0 -diaminodiphenylsulfone) is commonly used for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in immunocompromised patients. Oxidant hemolysis is a known complication of dapsone, but its frequency in adult patients who have undergone a SCT for hematological malignancies is not well established. We studied the presence of oxidant hemolysis, by combining examination of RBC morphology and laboratory data, in 30 patients who underwent a SCT and received dapsone for PCP prophylaxis, and compared this group with 26 patients who underwent a SCT and received trimethoprimsulfamethoxazole (TMP-SMX) for PCP prophylaxis. All patients had normal glucose-6-phosphate dehydrogenase (G6PDH) enzymatic activity. In SCT patients, dapsone compared with TMP-SMX for PCP prophylaxis was associated with a high incidence of oxidant hemolysis (87 vs 0%, Po0.001), and the morphological evaluation of oxidant hemolysis correlated well with laboratory evidence of hemolysis. Dapsone-induced oxidant hemolysis in SCT patients is 20-fold higher than the reported rate in the population of HIV-infected patients, and thus much higher than the prevalence of G6PDH variants in the general population. In our patients, it manifested clinically as a lower Hb that was not significant enough to result in increased packed RBC transfusions.
Introduction
Pneumocystis jirovecii Pneumonia (PCP) is a serious and potentially life-threatening infection that can occur in immunocompromised individuals. Patients who undergo a SCT routinely receive PCP prophylaxis for 6-12 months post-transplant. 1 Prevention of PCP can be successfully achieved in this patient population by prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX). 2 Alternative prophylactic agents, including dapsone, aerosolized pentamidine or atovaquone, have been proposed in cases of intolerance/allergy and neutropenia due to TMP-SMX. [3] [4] [5] Dapsone (4-4 0 -diaminodiphenylsulfone) is a commonly used alternative to TMP-SMX for PCP prophylaxis in immunocompromised patients, 3 Dapsone has relatively few side effects, although rare, but serious complications (agranulocytosis, aplastic anemia and 'sulfone syndrome') have been described. 6, 7 More commonly reported adverse hematological effects include hemolytic anemia and methemoglobinemia 3, 6 estimated to occur in 4-5% of HIVinfected patients on dapsone prophylaxis. 8 Dapsoneinduced hemolysis is thought to involve the generation of free radicals by its metabolite, hydroxylamine and subsequent depletion of RBC glutathione stores 9, 10 Therefore, screening for glucose-6-phosphate dehydrogenase (G6PDH) deficiency is recommended before the drug is started, in order to prevent potential hemolytic reactions.
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The morphological hallmark of RBC oxidant hemolysis is the presence of numerous bite cells or cells with irregularly contracted hemoglobin on one side (eccentrocytes) in a PB smear. 12 A high prevalence of dapsone-induced hemolytic anemia (up to fivefold higher than the reported rate in HIV patients) has been reported in solid organ transplant recipients receiving dapsone 13, 14 The frequency of oxidant hemolysis in adult patients taking dapsone as PCP prophylaxis following a hematopoietic SCT is not well established. 15 We studied the prevalence of oxidant hemolysis associated with dapsone use in SCT patients in the absence of G6PDH deficiency, and compared those findings in a control cohort consisting of patients who received TMP-SMX after SCT.
Patients and methods
We conducted a retrospective study on 56 patients who underwent a SCT at the Medical College of Wisconsin between January 2006 and December 2009 and who received dapsone or TMP-SMX for PCP prophylaxis for more than 1 week by day 100 after transplantation. Of these, 30 patients (29 Caucasian and 1 African-American) received dapsone (100 mg orally daily) for PCP prophylaxis and had undergone allogeneic (n ¼ 27) or autologous SCT (n ¼ 3) for hematological malignancy or aplastic anemia. They were compared with a control group of 26 (all Caucasian) patients receiving TMP-SMX for PCP prophylaxis. All patients from this control group had undergone allogeneic (n ¼ 22) or autologous SCT (n ¼ 4) for hematological malignancy or aplastic anemia. Patients had to be free of residual or relapsed disease during the time the study was conducted.
To determine the frequency of oxidant hemolysis, Wright Giemsa-stained PB smears were retrospectively reviewed in a blinded manner by three hematopathologists (HO, SHK and AMH) for the presence of bite cells, eccentrocytes and polychromasia by examining 420, 50 Â high-power fields. The presence of 42-3 bite cells and/or eccentrocytes/50 Â HPF was considered positive for morphological evidence of oxidant hemolysis, with consensus interpretations obtained in each case. PB smears from patients while on dapsone were compared with PB smears from SCT patients receiving TMP-SMX for PCP prophylaxis, serving as controls. Additional demographical and laboratory data, including G6PDH enzyme levels, Hb, reticulocyte count, haptoglobin, lactate dehydrogenase (LDH) and bilirubin levels, were collected from chart review. Patients intolerant of TMP-SMX were given dapsone 100 mg (after confirming that they were not G6PDH deficient) divided into two daily administrations (50 mg orally twice daily) to avoid a high-peak serum level that may correlate with hematological toxicities. Both types of prophylaxis were continued until 6 months post-transplant or longer, if the patient had clinical evidence of chronic GVHD or continued to receive systemic immunosuppressive therapy.
Statistical analysis
Statistical analyses of data were carried out in GraphPad Prism, version 5.0 b. (GraphPad Software, San Diego, CA, USA). Variables between groups were compared by Fisher's exact test and Student's T-test; a P-valueo0.05 was considered statistically significant. Table 1 summarizes the baseline clinical and laboratory features of the 56 patients. Patients receiving dapsone vs TMP-SMX were similar with regards to age, gender, ethnicity, indication for transplant, type of transplant and pre-transplant Hb. The vast majority of patients was Caucasian and received an allo-SCT for a hematological malignancy. Other factors potentially associated with hemolysis, such as ABO incompatibility, type of hematological malignancy (CLL/small lymphocytic lymphoma) and GVHD prophylaxis were similar between the two groups; specifically, two patients while on dapsone, and four patients while on TMP-SMX, respectively, were also receiving Sirolimus at the time of the study.
Results

Patient characteristics
Morphological and laboratory evaluation of oxidant hemolysis A total of 38 PB smears were reviewed from the 30 patients while on dapsone (some patients had more than one PB available). For comparison, 31 PB smears from the 26 patients receiving TMP-SMX, were also reviewed for evidence of oxidant hemolysis. The median time after SCT these PB smears were examined was 110 days (range, 40-255 days) in the dapsone group, and 100 days (range, 40-291 days) in the TMP-SMX group. Patients receiving dapsone had PB smears examined at a median of 13 days (range, 7-36 days) since initiation of PCP prophylaxis, and after receiving a median of 12 doses (range, 7-61) of dapsone. Figure 1 is a representative microphotograph of the PB smear from a patient demonstrating numerous bite cells (while on dapsone), as evidence of oxidant hemolysis. (Table 2) . Baseline pre-SCT Hb levels were comparable in patients before receiving dapsone and TMP-SMX, respectively (P ¼ 0.155). After initiation of PCP prophylaxis, Hb levels were lower in the dapsone group, compared with control patients (P ¼ 0.034). Mean LDH and indirect bilirubin were also increased in patients on dapsone, compared with patients on TMP-SMX (Po0.001). Mean LDH and indirect bilirubin levels were also significantly higher in patients while on dapsone, when compared with their baseline values (246 ± 31 U/L and 0.65 ± 12 mg/dL, respectively) (P ¼ 0.002). Patients more frequently had an elevated absolute reticulocyte count when receiving dapsone (16/30, 53%) than those receiving TMP-SMX (3/26, 12%) (P ¼ 0.002). Haptoglobin levels were available in a subset of patients. None of the patients (0/10, 0%) had low haptoglobin while on TMP-SMX, as compared with 9/13 (69%) patients on dapsone (P ¼ 0.002).
RBC transfusion requirements were comparable in patients receiving dapsone and those receiving TMP-SMX (P ¼ 0.764). None of the patients receiving dapsone for PCP prophylaxis required interruption of dapsone administration due to severe hemolytic anemia. No patient developed PCP, regardless of the prophylactic regimen (dapsone vs TMP-SMX) used.
Discussion
We conducted a retrospective study of 56 patients who underwent a SCT at the Medical College of Wisconsin over a period of 3 years, to investigate the incidence of dapsoneinduced oxidant hemolysis when this agent was used as PCP prophylaxis. For this purpose, we compared a cohort of patients receiving dapsone with a group of patients receiving TMP-SMX. The patients were appropriately matched in terms of type of SCT (autologous vs allogeneic) and donor type (related vs unrelated). We observed a higher proportion of morphological evidence of oxidant hemolysis in patients while on dapsone (87% of patients), as compared with patients receiving TMP-SMX (0% of patients). The morphological impression of frequent bite cells in dapsone cases correlated well with other laboratory parameters indicative of hemolysis, such as low Hb and haptoglobin, elevated LDH, absolute reticulocyte count and indirect bilirubin. It is important to note that although these findings are indicative of an ongoing oxidative hemolytic process, the changes in Hb were not severe enough to suspend administration of dapsone in any of the patients. Blood usage was similar between the dapsone and TMP-SMX groups, suggesting that the oxidative hemolysis in dapsone patients did not have a major clinical impact. Patients did, however, have a lower Hb level when they were on dapsone, compared with other patients receiving TMP-SMX.
A previous study that had investigated the hematological toxicity and efficacy of daily dapsone as second-line PCP prophylaxis in patients that underwent a SCT, did report a higher RBC and platelet transfusion requirement only in patients who were switched from TMP-SMX to dapsone after transplantation for reasons other than TMP-SMX allergy. 15 The same study found no differences in toxicity among patients who started their second-line dapsone PCP prophylaxis because of allergy or intolerance to TMP-SMX. 15 These findings suggest that even when some degree of drug-associated toxicity is taken into account, the higher transfusion requirements in a subset of SCT patients on dapsone may rather be due to underlying poor marrow reserve, as exemplified by a combined increase in both RBC and platelet transfusions. Of note, the above-mentioned study had a 12% rate of clinical adverse effects associated with dapsone, which led to drug discontinuation or temporary suspension in 10% of cases. 15 Another retrospective study of 43 lung allograft recipients described a 23% incidence of hemolytic anemia (defined as low serum haptoglobin with a simultaneous decrease in serum Hb) in patients receiving 100 mg daily dapsone for PCP prophylaxis. 13 Hemolysis occurred in all 10 patients within 5 months (range 46-156 days; median, 83 days) of dapsone initiation. In a similar study, out of 21 solid organ transplant recipients (kidney, lung, liver or heart) with possible dapsonerelated adverse events, 16 patients (76%) had laboratory findings consistent with hemolytic anemia.
14 Available literature data have estimated that B4% of patients on prophylactic doses of dapsone develop some degree of hemolytic anemia or methemoglobinemia. 3, 11, 16, 17 On the basis of these numbers, derived mostly from HIVinfected individuals, the rate of dapsone-induced oxidant hemolysis observed in our SCT patient cohort is 20-fold higher. Although the most common mechanism of oxidant hemolysis is G6PDH deficiency, which is found in more than 400 million people worldwide, 12 all patients receiving dapsone in this study had a negative fluorescent screening test for G6PDH activity. It is possible that other mutations in the hexose monophosphate shunt and glutathione metabolism pathways may have been present in some of the patients, and potentially caused a propensity to oxidant hemolysis. However, these other enzyme deficiencies are even less frequent in the general population, compared with G6PDH deficiency. The mechanism for such a high incidence of oxidative hemolysis in this patient population is unknown. Of note, forms of PCP prophylaxis other than TMP-SMX and dapsone, such as pentamidine, do not provide toxoplasmosis prophylaxis, and the transplant population is at very high risk for reactivating toxoplasmosis, if placed on one of these particular agents for PCP prophylaxis [3] [4] [5] As such, although oxidant hemolysis is a concern while patients are on dapsone, this should not necessarily be a reason for taking a patient of dapsone, especially if the only other PCP prophylaxis is not preventative against toxoplasmosis.
In summary, morphological evaluation of oxidant hemolysis correlates well with laboratory evidence of hemolytic anemia in SCT patients receiving dapsone for PCP prophylaxis. In our patient population, TMP-SMX prophylaxis for PCP is not associated with oxidant hemolysis. Dapsone-induced oxidant hemolysis in SCT patients is 20-fold higher than the reported rate in the population of HIV-infected patients, and thus much higher than the prevalence of G6PDH variants in the general population. In our patients it manifested clinically as a lower Hb that was not significant enough to result in increased packed RBC transfusions. Future studies exploring the mechanism for the high incidence of dapsoneinduced oxidative hemolysis in the setting of SCT are required.
